Compare HAE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAE | ELVN |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.2B |
| IPO Year | 1996 | 2020 |
| Metric | HAE | ELVN |
|---|---|---|
| Price | $118.98 | $37.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $124.50 | $73.92 |
| AVG Volume (30 Days) | 620.2K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $910,373,000.00 | N/A |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | $168.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.98 | $14.79 |
| 52 Week High | $123.77 | $62.32 |
| Indicator | HAE | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.45 | 18.98 |
| Support Level | $100.92 | $25.63 |
| Resistance Level | N/A | $40.62 |
| Average True Range (ATR) | 3.43 | 1.78 |
| MACD | 1.11 | -0.26 |
| Stochastic Oscillator | 79.00 | 7.25 |
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.